| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
NVO Stock Overview
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.
Rewards
Risk Analysis
No risks detected for NVO from our risk checks.
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.104.81 |
| 52 Week High | kr.122.16 |
| 52 Week Low | kr.91.51 |
| Beta | 0.26 |
| 1 Month Change | -7.23% |
| 3 Month Change | 0.73% |
| 1 Year Change | 0.77% |
| 3 Year Change | 102.26% |
| 5 Year Change | 131.01% |
| Change since IPO | 20,967.38% |
Recent News & Updates
Novo Nordisk goes ex-dividend tomorrow
Novo Nordisk (NVO) declared $0.411/share dividend. Payable Aug. 23; for shareholders of record Aug. 15; ex-div Aug. 12. See NVO Dividend Scorecard, Yield Chart, & Dividend Growth.
Novo Nordisk achieves positive data with two hemophilia candidates
Two Novo Nordisk (NVO) candidates for hemophilia garnered positive results, one in a phase 3 study and the other in a phase 1/2 trial. Phase 3 results on concizumab for hemophilia A or B showed the anti-tissue factor pathway inhibitor (TFPI) antibody along with inhibitors led to an 86% reduction in treated spontaneous and traumatic bleeds, with an estimated mean annual bleeding rate of 1.7 compared to 11.8 without concizumab. Novo Nordisk (NVO) said it plans on regulatory filings for concizumab in the second half of this in the US and Japan, and in 2023 in the EU and the UK. Separately, there were no thromboembolic events or serious adverse events reported in a phase 1/2 trial of next-generation Factor VIIIa (FVIIIa) mimetic Mim8. Novo Nordisk (NVO) said dosing in the phase 3 trial should begin in Q4. Seeking Alpha's Quant Rating views Novo Nordisk as a hold with high grades for profitability, revisions, and momentum.
Shareholder Returns
| NVO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.5% | -0.06% | 1.1% |
| 1Y | 0.8% | 0.6% | -9.0% |
Return vs Industry: NVO exceeded the US Pharmaceuticals industry which returned -0.9% over the past year.
Return vs Market: NVO exceeded the US Market which returned -8.9% over the past year.
Price Volatility
| NVO volatility | |
|---|---|
| NVO Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 12.1% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NVO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: NVO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 50,816 | Lars Jorgensen | https://www.novonordisk.com |
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.
Novo Nordisk A/S Fundamentals Summary
| NVO fundamental statistics | |
|---|---|
| Market Cap | US$239.45b |
| Earnings (TTM) | US$6.91b |
| Revenue (TTM) | US$21.50b |
34.7x
P/E Ratio11.1x
P/S RatioIs NVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVO income statement (TTM) | |
|---|---|
| Revenue | kr.157.25b |
| Cost of Revenue | kr.25.29b |
| Gross Profit | kr.131.97b |
| Other Expenses | kr.81.43b |
| Earnings | kr.50.54b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 02, 2022
| Earnings per share (EPS) | 22.30 |
| Gross Margin | 83.92% |
| Net Profit Margin | 32.14% |
| Debt/Equity Ratio | 34.2% |
How did NVO perform over the long term?
See historical performance and comparison